Entest Group, Inc. Watch

from 8-K 1 page Therefore, It Is Agreed as Follows: 1. Stock in Satisfaction of Settlement Debt. on or Before , May 31 2017 Creditor Will Issue to Debtor 199,000 Newly Issued Shares of the Creditor’s Non Voting Convertible Preferred Stock in Full Satisfaction of the Settlement Debt

from 8-K 1 page Debt Satisfaction Agreement (“Agreement”) Entered Into by and Between Entest Biomedical, Inc. (“Debtor”) and Bostonia Partners Inc. (“Creditor”) Dated May 25, 2017. Whereas, as of May 25, 2017 , Debtor Is Indebted to Creditor in the Principal Amount of $327,681. Whereas Debtor Wishes to Accept Equity Securities of Creditor in Satisfaction of $327,681 of the Total Principal Debt Due to Debtor From Creditor (“Settlement Debt”) Therefore, It Is Agreed as Follows: 1. Stock in Satisfaction of Settlement Debt. on or Before , May 31 2017 Creditor Will Issue to Debtor 327,681 Newly Issued Shares of the Creditor’s Non Voting Convertible Preferred Stock in Full Satisfaction of the Settlement Debt

from 8-K 1 page Debt Satisfaction Agreement (“Agreement”) Entered Into by and Between Entest Biomedical, Inc. (“Debtor”) and Dunhill Ross Partners Inc. (“Creditor”) Dated May 25, 2017. Whereas, as of May 25, 2017 , Debtor Is Indebted to Creditor in the Principal Amount of $165,850. Whereas Debtor Wishes to Accept Equity Securities of Creditor in Satisfaction of $165,850 of the Total Principal Debt Due to Debtor From Creditor (“Settlement Debt”) Therefore, It Is Agreed as Follows: 1. Stock in Satisfaction of Settlement Debt. on or Before , May 31 2017 Creditor Will Issue to Debtor 165,850 Newly Issued Shares of the Creditor’s Non Voting Convertible Preferred Stock in Full Satisfaction of the Settlement Debt

from 8-K 1 page Debt Satisfaction Agreement (“Agreement”) Entered Into by and Between Entest Biomedical, Inc. (“Debtor”) and Biotechnology Partners Business Trust (“Creditor”) Dated May 25, 2017. Whereas, as of May 25, 2017 , Debtor Is Indebted to Creditor in the Principal Amount of $149,000. Whereas Debtor Wishes to Accept Equity Securities of Creditor in Satisfaction of $149,000 of the Total Principal Debt Due to Debtor From Creditor (“Settlement Debt”) Therefore, It Is Agreed as Follows: 1. Stock in Satisfaction of Settlement Debt. on or Before , May 31 2017 Creditor Will Issue to Debtor 149,000 Newly Issued Shares of the Creditor’s Non Voting Convertible Preferred Stock in Full Satisfaction of the Settlement Debt

from 8-K 1 page Debt Satisfaction Agreement (“Agreement”) Entered Into by and Between Entest Biomedical, Inc. (“Debtor”) and Regen Biopharma, Inc. (“Creditor”) Dated May 25, 2017. Whereas, as of May 25, 2017 , Debtor Is Indebted to Creditor in the Principal Amount of $83,000. Whereas Debtor Wishes to Accept Equity Securities of Creditor in Satisfaction of $83,000 of the Total Principal Debt Due to Debtor From Creditor (“Settlement Debt”) Therefore, It Is Agreed as Follows: 1. Stock in Satisfaction of Settlement Debt. on or Before , May 31 2017 Creditor Will Issue to Debtor 83,000 Newly Issued Shares of the Creditor’s Non Voting Convertible Preferred Stock in Full Satisfaction of the Settlement Debt

from 10-K 1 page Line of Credit Promissory Note

from 10-K/A 1 page Line of Credit Promissory Note

from S-1/A 20 pages Neither the Issuance and Sale of the Securities Represented by This Certificate Nor the Securities Into Which These Securities Are Convertible Have Been Registered Under the Securities Act of 1933, as Amended, or Applicable State Securities Laws. the Securities May Not Be Offered for Sale, Sold, Transferred or Assigned (I) in the Absence of (A) an Effective Registration Statement for the Securities Under the Securities Act of 1933, as Amended, or (B) an Opinion of Counsel (Which Counsel Shall Be Selected by the Holder), in a Generally Acceptable Form, That Registration Is Not Required Under Said Act or (II) Unless Sold Pursuant to Rule 144 or Rule 144a Under Said Act. Notwithstanding the Foregoing, the Securities May Be Pledged in Connection With a Bona Fide Margin Account or Other Loan or Financing Arrangement Secured by the Securities. Principal Amount: $63,000.00 Issue Date: July 26, 2012 Purchase Price: $63,000.00 Convertible Promissory Note

from S-1 1 page Line of Credit Promissory Note

from S-1 1 page Line of Credit Promissory Note

from S-1 1 page Line of Credit Promissory Note

from S-1 1 page Line of Credit Promissory Note

from S-1 1 page Line of Credit Promissory Note

from S-1 1 page Line of Credit Promissory Note

from S-1 1 page Line of Credit Promissory Note

from S-1 1 page Line of Credit Promissory Note

from 10-K 10 pages Neither the Issuance and Sale of the Securities Represented by This Certificate Nor the Securities Into Which These Securities Are Convertible Have Been Registered Under the Securities Act of 1933, as Amended, or Applicable State Securities Laws. the Securities May Not Be Offered for Sale, Sold, Transferred or Assigned (I) in the Absence of (A) an Effective Registration Statement for the Securities Under the Securities Act of 1933, as Amended, or (B) an Opinion of Counsel (Which Counsel Shall Be Selected by the Holder), in a Generally Acceptable Form, That Registration Is Not Required Under Said Act or (II) Unless Sold Pursuant to Rule 144 or Rule 144a Under Said Act. Notwithstanding the Foregoing, the Securities May Be Pledged in Connection With a Bona Fide Margin Account or Other Loan or Financing Arrangement Secured by the Securities. Principal Amount: $32,500.00 Issue Date: October 25, 2011 Purchase Price: $32,500.00 Convertible Promissory Note

from 10-K 10 pages Neither the Issuance and Sale of the Securities Represented by This Certificate Nor the Securities Into Which These Securities Are Convertible Have Been Registered Under the Securities Act of 1933, as Amended, or Applicable State Securities Laws. the Securities May Not Be Offered for Sale, Sold, Transferred or Assigned (I) in the Absence of (A) an Effective Registration Statement for the Securities Under the Securities Act of 1933, as Amended, or (B) an Opinion of Counsel (Which Counsel Shall Be Selected by the Holder), in a Generally Acceptable Form, That Registration Is Not Required Under Said Act or (II) Unless Sold Pursuant to Rule 144 or Rule 144a Under Said Act. Notwithstanding the Foregoing, the Securities May Be Pledged in Connection With a Bona Fide Margin Account or Other Loan or Financing Arrangement Secured by the Securities. Principal Amount: $35,000.00 Issue Date: August 23, 2011 Purchase Price: $35,000.00 Convertible Promissory Note

from 10-K 10 pages Neither the Issuance and Sale of the Securities Represented by This Certificate Nor the Securities Into Which These Securities Are Convertible Have Been Registered Under the Securities Act of 1933, as Amended, or Applicable State Securities Laws. the Securities May Not Be Offered for Sale, Sold, Transferred or Assigned (I) in the Absence of (A) an Effective Registration Statement for the Securities Under the Securities Act of 1933, as Amended, or (B) an Opinion of Counsel (Which Counsel Shall Be Selected by the Holder), in a Generally Acceptable Form, That Registration Is Not Required Under Said Act or (II) Unless Sold Pursuant to Rule 144 or Rule 144a Under Said Act. Notwithstanding the Foregoing, the Securities May Be Pledged in Connection With a Bona Fide Margin Account or Other Loan or Financing Arrangement Secured by the Securities. Principal Amount: $37,500.00 Issue Date: July 5, 2011 Purchase Price: $37,500.00 Convertible Promissory Note

from 10-K 10 pages Neither the Issuance and Sale of the Securities Represented by This Certificate Nor the Securities Into Which These Securities Are Convertible Have Been Registered Under the Securities Act of 1933, as Amended, or Applicable State Securities Laws. the Securities May Not Be Offered for Sale, Sold, Transferred or Assigned (I) in the Absence of (A) an Effective Registration Statement for the Securities Under the Securities Act of 1933, as Amended, or (B) an Opinion of Counsel (Which Counsel Shall Be Selected by the Holder), in a Generally Acceptable Form, That Registration Is Not Required Under Said Act or (II) Unless Sold Pursuant to Rule 144 or Rule 144a Under Said Act. Notwithstanding the Foregoing, the Securities May Be Pledged in Connection With a Bona Fide Margin Account or Other Loan or Financing Arrangement Secured by the Securities. Principal Amount: $42,500.00 Issue Date: May 20, 2011 Purchase Price: $42,500.00 Convertible Promissory Note